may offer dermatologic benefits but also raise skin, aesthetic surgery, wound healing, and perioperative risks.
Evidence
This narrative review summarizes current evidence on GLP-1 receptor agonists in dermatologic conditions, cutaneous adverse reactions, aesthetic and reconstructive surgery, and perioperative management.
Caveat
The abstract synthesizes emerging and context-specific evidence rather than reporting new clinical outcome data or quantified risk estimates.
Simplified
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have gained prominence for their efficacy in treating type 2 diabetes and obesity. Recent evidence suggests that their pleiotropic effects-beyond glycemic control and weight loss-include anti-inflammatory, immunomodulatory, and antioxidative effects, which may beneficially support various dermatologic conditions such as , , acanthosis nigricans, and Hailey-Hailey disease. However, GLP-1 RAs are also associated with emerging cutaneous adverse drug reactions, including bullous, exanthematous and vasculitic manifestations, and other rare side effects. In aesthetic and reconstructive surgery, rapid weight loss induced by these agents has raised concerns regarding facial volume depletion, skin laxity, and impaired wound healing. In addition, perioperative management of patients on GLP-1 RAs requires careful assessment as a result of delayed gastric emptying and the associated potential risk of pulmonary aspiration. This narrative review summarizes current knowledge on the benefit/risk profile of GLP-1 RAs, highlighting their impact for dermatologists and plastic surgeons in relevant contexts.
Full Text
We can’t show the full text here under this license.
